Fig. 4: DUSP6 inhibitor accelerated the bone loss in vivo. | Cell Death & Disease

Fig. 4: DUSP6 inhibitor accelerated the bone loss in vivo.

From: DUSP6 expression is associated with osteoporosis through the regulation of osteoclast differentiation via ERK2/Smad2 signaling

Fig. 4

Experimental osteoporosis model was established. Mice were treated with (E/Z)-BCI for analysis the function of DUSP6 in vivo. A uCT was analyzed to confirm the bone loss. B The tibia was collected from the indicated groups and TRAP staining was analyzed to detect the osteoclasts. Original scale bars: 500 μm. C Quantitative analysis was used to determine the average TRAP-positive cell numbers from five different versions and the TRAP-positive cell bone surface/bone surface. D Serum cross-linked C-telopeptide 1 levels were determined by ELISA (mouse CTx-I ELISA kit; Cusabio, Wuhan, China). E The bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation (Tb.Sp) were measured to evaluate the microstructure. F The tibia was collected from the indicated groups. Immunofluorescence assay was carried out to explore the expression of DUSP6 in the indicated groups. Original scale bars: 500 μm.The tibia was collected from the indicated groups. Immunohistochemistry and quantitative analysis were carried out to explore the expression of ACP5 and CTSK, which were identified as osteoclast markers (G, H). Original scale bars: 500 μm. Data in all bar graphs are expressed as mean ± SD (n = 5). *P < 0.05, #P < 0.01.

Back to article page